Pacira (PCRX) BioSciences announced its board of directors has authorized a share repurchase program of up to an aggregate of $300M of the company’s common stock. The program replaces the prior authorization announced in May 2024 under the same terms and expires at the end of December 2026. The company said the authorization underscores the board’s confidence in Pacira’s growth strategy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira reports inducement grants under Nasdaq listing rule
- Pacira price target raised to $28 from $25 at Truist
- Positive Outlook for Pacira Pharmaceuticals Amid Exparel Settlement and Strategic Growth Initiatives
- Pacira price target raised to $26 from $22 at RBC Capital
- Pacira price target raised to $65 from $48 at H.C. Wainwright